JBS Reports Record Revenue but Swings to Net Loss in Q2 2026
Key Takeaways
- JBS swung to a net loss of $102 million in Q2 2026, reversing a $528 million profit from the same quarter last year, driven by non-recurring charges and persistent margin pressure in North American beef.
- Revenue reached an all-time quarterly record of $23.9 billion, up 14% year-over-year and comfortably ahead of the $23.1 billion consensus estimate, reflecting strong global protein demand and higher selling prices.
- Adjusted earnings per share (EPS) came in at $0.20, missing analyst expectations of approximately $0.31 to $0.33, while adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $1.43 billion narrowly topped the $1.42 billion consensus.
- JBS Beef North America posted a negative adjusted EBITDA of $78 million, as record-high live cattle prices continued to outpace beef cutout values, though this marked an improvement from a $233 million loss a year earlier.
- The company paid a $1 billion dividend and announced a CEO transition plan, with Wesley Batista Filho set to succeed Gilberto Tomazoni in January 2027.
Why These Results Matter
JBS, the world’s largest protein producer, operates a uniquely diversified platform spanning beef, pork, poultry, and value-added products across North America, South America, Australia, and Europe. This Q2 2026 report arrives at a critical juncture: the company is navigating a severe U.S. cattle supply shortage that has squeezed beef margins for multiple quarters, while simultaneously managing softening poultry prices from increased production. The results also carry heightened significance because they mark JBS’s first quarterly filing as a U.S. domestic SEC registrant on Form 10-Q, a voluntary transition designed to broaden index eligibility and attract passive investment flows. With 13 of 15 analysts rating the stock a Buy and a mean price target implying roughly 29% upside heading into the print, investor expectations for a margin recovery narrative were high. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Digging Into the Numbers
JBS reported Q2 2026 net revenue of $23.9 billion, a 14% increase from $21.0 billion in the prior-year period and above the $23.1 billion consensus estimate. The top-line strength was broad-based, with record quarterly sales in JBS Brazil, JBS Beef North America, and the Australia division. However, gross profit contracted to $2.59 billion from $2.83 billion year-over-year, reflecting elevated livestock procurement costs across multiple regions.
The company posted a net loss of $102 million, or $0.10 per share, compared to a profit of $528 million, or $0.48 per share, in Q2 2025. The loss was heavily influenced by non-recurring items, including $172 million in premiums and costs associated with bond and CRA (Certificados de Recebíveis do Agronegócio, or Agribusiness Receivables Certificates) tender offers, and $133 million in antitrust settlement charges. Excluding these items, adjusted net income was $218 million, or $0.20 per share — below the $0.31 to $0.33 consensus.
Adjusted EBITDA under IFRS (International Financial Reporting Standards) declined 18% year-over-year to $1.43 billion, with the margin compressing to 6.0% from 8.4%. Under U.S. GAAP (Generally Accepted Accounting Principles), adjusted EBITDA was $1.257 billion, down 8%. The discrepancy versus consensus expectations was largely attributable to a tougher-than-anticipated poultry pricing environment and continued losses in the U.S. beef segment. JBS Beef North America generated record revenue of $7.77 billion but recorded a negative adjusted EBITDA of $78 million. Pilgrim’s Pride, the company’s majority-owned poultry subsidiary, saw adjusted EBITDA drop 38.5% to $503 million as elevated industry-wide chicken production pressured prices. In contrast, JBS Brazil delivered record Q2 revenue of $4.59 billion and a 17.8% increase in adjusted EBITDA to $269 million, driven by strong domestic demand and robust exports to China. To get a broader view of similar names, I ran a quick comparison through Tickeron’s AI Screener.
Market Response to the Earnings
Heading into the August 10 after-market release, JBS shares traded at $14.23, having pulled back considerably from a 52-week high of $18.65. The stock had declined approximately 6% in the trading session prior to the announcement, reflecting cautious positioning. The mixed results — record revenue offset by an earnings miss and a net loss — place the stock in a delicate position. On one hand, the revenue beat and marginally higher-than-expected adjusted EBITDA demonstrate the resilience of JBS’s diversified global platform. On the other hand, the adjusted EPS miss and the scale of non-recurring charges may temper enthusiasm. JPMorgan’s late-July upgrade to Buy with an $18 price target signaled that institutional sentiment viewed the selloff as overdone, but the earnings release will test that thesis. The $1 billion dividend payout and the CEO succession announcement add layers of complexity to the narrative that investors must digest.
Looking Ahead: Key Factors to Watch
Looking ahead, several developments will shape JBS’s trajectory through the second half of 2026 and into 2027. The most immediate catalyst is the anticipated easing of U.S. cattle import restrictions from Mexico, which the company expects to begin later in August. The U.S.-Mexico cattle border had been constrained by screwworm cases, and a phased reopening could gradually alleviate the livestock supply bottleneck that has plagued North American beef margins. However, the timing means any meaningful financial benefit will likely materialize in subsequent quarters rather than providing an immediate turnaround. I’m watching this closely as it could ease some of the margin pressure we’ve seen.
On the poultry side, investors should monitor whether the industry responds to oversupply conditions with production discipline. Pilgrim’s Pride’s margin compression reflects a broader dynamic where improved bird health, lower avian influenza disruptions, and favorable feed costs have encouraged expanded output — ultimately weighing on chicken prices. Any signal of production cuts or demand recovery in key export markets would be a positive development for segment profitability.
The leadership transition adds another dimension. Wesley Batista Filho, 34, currently leads JBS’s U.S. operations and has been the presumed successor to long-time CEO Gilberto Tomazoni. His elevation to global CEO in January 2027 represents a generational shift at the top of the company. Early indications suggest strategic continuity, but the market will closely watch any adjustments to capital allocation priorities, geographic focus, or operational structure under new leadership.
Additional factors to track include the progress of the $2.5 billion joint venture with Indonesia’s sovereign wealth fund Danantara, which targets Asia-Pacific protein investments and signals JBS’s appetite for geographic expansion. Leverage, which rose to 3.1 times net debt-to-EBITDA from 2.27 times a year earlier, will also remain in focus. While the company boosted total liquidity to $7.7 billion through an expanded revolving credit facility in August, the metric sits slightly above the firm’s long-term target range of 2.0 to 3.0 times. How management balances growth investment, shareholder returns, and deleveraging will be a central theme for the quarters ahead. One thing that stands out here is how these moving parts could influence the stock’s path.
Enhancing Research with AI Tools
When analyzing complex earnings like these, I often use Tickeron’s AI Screener to quickly filter stocks in the protein and consumer staples sectors. It helps surface relevant ideas by applying customizable criteria such as industry classification, technical patterns, and AI-driven signals, allowing me to compare JBS against peers efficiently and refine my perspective on the broader group.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JBS in upward trend: price rose above 50-day moving average on July 24, 2026
JBS moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend. In of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where JBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The 10-day moving average for JBS crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JBS advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 234 cases where JBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for JBS moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JBS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JBS turned negative on August 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JBS broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.528) is normal, around the industry mean (8.481). P/E Ratio (12.916) is within average values for comparable stocks, (36.558). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.944). Dividend Yield (0.072) settles around the average of (0.055) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (5.907).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement